Company Description
Vectura helps customers succeed in bringing their inhaled medicines to market with a unique combination of formulation science, device technology and inhaled product development expertise. From one-off studies and specialist techniques through to full development services, we help customers, ranging from small biotech to large pharmaceutical companies, progress their inhaled programmes at every stage of development.
With more than 20 years’ experience, we have a rich scientific heritage and reputation for delivering success for our customers, with leading formulation and device technologies across a range of platforms: dry powder inhalers (DPIs) and smart nebulisers.
Company Background
Vectura integrates formulation, device, and development capabilities to offer a broad range of services to help customers bring inhaled medicines to market. The company’s track record offers customers confidence in Vectura as a trusted development partner; since 2012, Vectura’s formulation and device technology have contributed to the success of 13 inhaled medicines, launched by partners and licensees, generating $10 billion in sales and used by 9 million patients worldwide.
Facilities
With extensive analytical testing facilities, Vectura can undertake the comprehensive array of test methodologies and physical properties characterization required for inhaled products, in addition to stability studies and device verification testing.
Vectura also offers seamless scale-up from laboratory to pilot to commercially-representative scale as well as GMP drug product and device manufacturing for clinical trials.